Literature DB >> 9226998

Therapeutic advances in amyotrophic lateral sclerosis.

E Louvel1, J Hugon, A Doble.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive and rapidly fatal neurodegenerative disease in which both upper and lower motoneurones are involved. The recent discovery of mutations affecting the superoxide dismutase (SOD) gene has given impetus to research on the role of oxidative stress in the pathogenesis of familial ALS, while further evidence for a role of excitotoxicity in the disease process has arisen. In this review, Erik Louvel, Jacques Hugon and Adam Doble discuss these findings and, in addition, describe how a number of large, well-controlled clinical trials have taken place to test potential therapies suggested by different aetiological hypotheses, including immunosuppressive therapies, neurotrophic factors, antioxidants and anti-excitotoxic drugs. These trials have led to the first modest steps in the treatment of this devastating neurological disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9226998     DOI: 10.1016/s0165-6147(97)01062-6

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  9 in total

1.  Riluzole treatment in advanced ALS.

Authors:  Gian Domenico Borasio
Journal:  J Neurol       Date:  2002-05       Impact factor: 4.849

2.  Regulation of glutamate transporters in astrocytes: evidence for a relationship between transporter expression and astrocytic phenotype.

Authors:  Chrissandra J Zagami; Ross D O'Shea; Chew L Lau; Surindar S Cheema; Philip M Beart
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

3.  Effects of silkworm larvae powder containing manganese superoxide dismutase on immune activity of mice.

Authors:  Wan-Fu Yue; Jian-Mei Liu; Guang-Li Li; Xing-Hua Li; Xiao-Feng Wu; Jian-Tong Sun; Hong-Xiang Sun; Yun-Gen Miao
Journal:  Mol Biol Rep       Date:  2007-06-29       Impact factor: 2.316

Review 4.  Diagnostic investigation and multidisciplinary management in motor neuron disease.

Authors:  J A Rocha; C Reis; F Simões; J Fonseca; J Mendes Ribeiro
Journal:  J Neurol       Date:  2005-12       Impact factor: 4.849

Review 5.  Issues for clinical drug development in neurodegenerative diseases.

Authors:  Michel Dib
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 6.  Amyotrophic lateral sclerosis: progress and prospects for treatment.

Authors:  Michel Dib
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Silkworm powder containing manganese superoxide dismutase regulated the immunity and inhibited the growth of Hepatoma 22 cell in mice.

Authors:  Wan-Fu Yue; Wen Deng; Xing-Hua Li; Bhaskar Roy; Guang-Li Li; Jian-Mei Liu; Xiao-Feng Wu; Hong-Xiang Sun; Min-Li Yao; Wan Chi Cheong David; Yun-Gen Miao
Journal:  Mol Biol Rep       Date:  2007-11-22       Impact factor: 2.316

8.  Manganese superoxide dismutase expressed in silkworm larvae, Bombyx mori L enhances the NK activity and splenocyte proliferation against Sarcoma 180 tumor cells in vivo.

Authors:  Wan-Fu Yue; Min-Li Yao; Jian-Mei Liu; Guang-Li Li; Xing-Hua Li; Xiao-Feng Wu; Wen Deng; Hong-Xiang Sun; Ji-Yong Zhou; Chuan-Xi Zhang; Yun-Gen Miao
Journal:  Mol Biol Rep       Date:  2007-10-14       Impact factor: 2.316

Review 9.  CRISPR/Cas9: a powerful genetic engineering tool for establishing large animal models of neurodegenerative diseases.

Authors:  Zhuchi Tu; Weili Yang; Sen Yan; Xiangyu Guo; Xiao-Jiang Li
Journal:  Mol Neurodegener       Date:  2015-08-04       Impact factor: 14.195

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.